Arcellx, Inc. (ACLX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 52.73 |
| Open | 51.81 |
| Bid | 49.70 x 200 |
| Ask | 49.93 x 400 |
| Day's range | 47.88 - 52.73 |
| 52-week range | 30.74 - 75.10 |
| Volume | |
| Avg. volume | 459,536 |
| Market cap | 2.661B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.03 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 80.31 |
- GuruFocus.com
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
Financial Outcomes Show Significant Improvement, Beating Revenue Estimates
ZacksArcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
© 2024 Yahoo. All rights reserved.